{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:11:02Z","timestamp":1781521862555,"version":"3.54.1"},"reference-count":102,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T00:00:00Z","timestamp":1653436800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Ropeginterferon alfa-2b is a novel mono-pegylated and extra-long-acting interferon, being developed for the treatment of myeloproliferative neoplasm (MPN) and chronic viral hepatitis. It has a favorable pharmacokinetic profile and less frequent dosing schedule, i.e., once every two to four weeks, compared to conventional pegylated interferon products, which have multiple isomers and are administered weekly. It was approved for the long-term treatment of polycythemia vera, an MPN, and has been included in the NCCN clinical practice guidelines for this indication. Ropeginterferon alfa-2b has demonstrated efficacy and showed a favorable safety profile for the treatment of chronic viral hepatitis in several clinical studies. In this article, we review its pharmacokinetics and available clinical data and suggest that ropeginterferon alfa-2b administered once every two weeks can serve as a new treatment option for patients with chronic viral hepatitis, including chronic hepatitis B, C, and D.<\/jats:p>","DOI":"10.3390\/v14061128","type":"journal-article","created":{"date-parts":[[2022,5,25]],"date-time":"2022-05-25T05:12:27Z","timestamp":1653455547000},"page":"1128","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Novel Pegylated Interferon for the Treatment of Chronic Viral Hepatitis"],"prefix":"10.3390","volume":"14","author":[{"given":"Yi-Wen","family":"Huang","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine and Clinical Research Center, Taipei Medical University Hospital, Taipei 110, Taiwan"},{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei 110, Taiwan"},{"name":"School of Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Qin","sequence":"additional","affiliation":[{"name":"PharmaEssentia Corporation, Taipei 115, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chan-Yen","family":"Tsai","sequence":"additional","affiliation":[{"name":"PharmaEssentia Corporation, Taipei 115, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8316-3785","authenticated-orcid":false,"given":"Pei-Jer","family":"Chen","sequence":"additional","affiliation":[{"name":"Graduate Institute of Clinical Medicine, National Taiwan University College of Medicine, Taipei 100, Taiwan"},{"name":"Hepatitis Research Center, National Taiwan University Hospital, Taipei 100, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,5,25]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S1046-5928(03)00055-X","article-title":"Isolation, structural characterization, and antiviral activity of positional isomers of monopegylated interferon alpha-2a (PEGASYS)","volume":"30","author":"Foser","year":"2003","journal-title":"Protein Expr. Purif."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0169-409X(02)00027-3","article-title":"Structural and biological characterization of pegylated recombinant interferon alpha-2b and its therapeutic implications","volume":"54","author":"Wang","year":"2002","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/bcp.15176","article-title":"Novel long-acting ropeginterferon alfa-2b: Pharmacokinetics, pharmacodynamics, and safety in a phase 1 clinical trial","volume":"88","author":"Huang","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"4756","DOI":"10.1007\/s12325-021-01863-y","article-title":"Pharmacokinetics and pharmacodynamics of novel long acting ropeginterferon alfa-2b in healthy Chinese subjects","volume":"38","author":"Huang","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1007\/s40261-021-01026-5","article-title":"Pharmacokinetics and pharmacodynamics of ropeginterferon alfa-2b in healthy Japanese and Caucasian subjects after single subcutaneous administration","volume":"41","author":"Miyachi","year":"2021","journal-title":"Clin. Drug Investig."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"e196","DOI":"10.1016\/S2352-3026(19)30236-4","article-title":"Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): A randomised, non-inferiority, phase 3 trial and its extension study","volume":"7","author":"Gisslinger","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_7","unstructured":"US FDA (2021, November 12). FDA Approves Treatment for Rare Blood Disease, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-treatment-rare-blood-disease."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"309","DOI":"10.36290\/vnl.2020.086","article-title":"Ropeginterferon alfa-2 b for the therapy of polycythemia vera","volume":"66","year":"2020","journal-title":"Vnitr. Lek."},{"key":"ref_9","unstructured":"The National Comprehensive Cancer Network (2022, May 12). Guidelines Panel for Myeloproliferative Neoplasms. Available online: https:\/\/www.nccn.org\/guidelines\/guidelines-detail?category=1&id=1477."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1002\/jgh3.12613","article-title":"Ropeginterferon alfa-2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy","volume":"5","author":"Lin","year":"2021","journal-title":"JGH Open"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jfma.2020.09.018","article-title":"Ropeginterferon alfa-2b administered every two weeks for patients with genotype 2 chronic hepatitis C","volume":"120","author":"Hsu","year":"2021","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s12072-020-10098-y","article-title":"Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B","volume":"14","author":"Huang","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"11033","DOI":"10.3748\/wjg.v20.i32.11033","article-title":"Chronic hepatitis C and liver fibrosis","volume":"20","author":"Sebastiani","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1002\/hep.27222","article-title":"Epidemiology of hepatocellular carcinoma in the United States: Where are we? Where do we go?","volume":"60","author":"Kanwal","year":"2014","journal-title":"Hepatology"},{"key":"ref_15","unstructured":"WHO (2022, May 12). Hepatitis C Fact Sheets (Updated July 2021). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-c."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"S45","DOI":"10.1016\/j.jhep.2014.07.027","article-title":"Global epidemiology and genotype distribution of the hepatitis C virus infection","volume":"61","author":"Gower","year":"2014","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1002\/hep.26744","article-title":"Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: Updated criteria and genotype assignment web resource","volume":"59","author":"Smith","year":"2014","journal-title":"Hepatology"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/hep.22070","article-title":"Mechanisms of action of interferon and ribavirin in chronic hepatitis C: Summary of a workshop","volume":"47","author":"Chung","year":"2008","journal-title":"Hepatology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.3389\/fimmu.2020.615603","article-title":"Interferon receptor trafficking and signaling: Journey to the cross roads","volume":"11","author":"Zanin","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Aric\u00f2, E., Castiello, L., Capone, I., Gabriele, L., and Belardelli, F. (2019). Type I interferons and cancer: An evolving story demanding novel clinical applications. Cancers, 11.","DOI":"10.3390\/cancers11121943"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1002\/hep.22253","article-title":"Randomized comparison of 12 or 24 weeks of peginterferon alpha-2a and ribavirin in chronic hepatitis C virus genotype 2\/3 infection","volume":"47","author":"Lagging","year":"2008","journal-title":"Hepatology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"7220","DOI":"10.3748\/wjg.14.7220","article-title":"Four-week pegylated interferon alpha-2a monotherapy for chronic hepatitis C with genotype 2 and low viral load: A pilot, randomized study","volume":"14","author":"Tsubota","year":"2008","journal-title":"World J. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1478-3231.2008.01736.x","article-title":"Eight-week regimen of antiviral combination therapy with peginterferon and ribavirin for patients with chronic hepatitis C virus genotype 2 and a rapid virological response","volume":"29","author":"Toyoda","year":"2009","journal-title":"Liver Int."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"9954","DOI":"10.1038\/srep09954","article-title":"Systematic review: Impact of interferon-based therapy on HCV-related hepatocellular carcinoma","volume":"5","author":"Hsu","year":"2015","journal-title":"Sci. Rep."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Hsu, C.-S., Huang, C.-J., Kao, J.-H., Lin, H.H., Chao, Y.-C., Fan, Y.-C., and Tsai, P.-S. (2013). Interferon-based therapy decreases risks of hepatocellular carcinoma and complications of cirrhosis in chronic hepatitis C patients. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0070458"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1159\/000337293","article-title":"A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: A novel approach by using meta-regression","volume":"82","author":"Shen","year":"2012","journal-title":"Oncology"},{"key":"ref_27","unstructured":"Merck Sharp & Dohme Corp. (2022, May 12). Package Insert: PEGINTRON\u00ae (Peginterferon alfa-2b), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/103949s5313lbl.pdf."},{"key":"ref_28","unstructured":"Roche (2022, May 12). Package Insert: PEGASYS\u00ae (Peginterferon alfa-2a), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/103964s5204lbl.pdf."},{"key":"ref_29","unstructured":"WHO (2022, May 12). Hepatitis B Fact Sheets (Updated July 2021). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-b."},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Tseng, T.-C., and Kao, J.-H. (2017). Elimination of hepatitis B: Is it a mission possible?. BMC Med., 15.","DOI":"10.1186\/s12916-017-0820-x"},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Alexopoulou, A., Vasilieva, L., and Karayiannis, P. (2020). New approaches to the treatment of chronic hepatitis B. J. Clin. Med., 9.","DOI":"10.3390\/jcm9103187"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1002\/hep4.1281","article-title":"Hepatitis B treatment: What we know now and what remains to be researched","volume":"3","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_33","first-page":"12","article-title":"Resistance associated mutations in HCV patients failing DAA treatment","volume":"44","author":"Faleo","year":"2021","journal-title":"New Microbiol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1002\/jmv.25022","article-title":"Virological patterns of HCV patients with failure to interferon-free regimens","volume":"90","author":"Starace","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1016\/j.jhep.2021.03.004","article-title":"Treatment failure with DAA therapy: Importance of resistance","volume":"74","author":"Sarrazin","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Malandris, K., Kalopitas, G., Theocharidou, E., and Germanidis, G. (2021). The role of RASs\/RVs in the current management of HCV. Viruses, 13.","DOI":"10.3390\/v13102096"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.jhep.2016.04.008","article-title":"Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy","volume":"65","author":"Reig","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/j.jhep.2016.06.015","article-title":"Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals","volume":"65","author":"Conti","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.jhep.2016.07.027","article-title":"High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy for hepatitis C associated cirrhosis","volume":"65","author":"Cardoso","year":"2016","journal-title":"J. Hepatol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s00005-018-0532-8","article-title":"Modulation of the immune system in chronic hepatitis C and during antiviral interferon-free therapy","volume":"67","author":"Urbanowicz","year":"2019","journal-title":"Arch. Immunol. Ther. Exp."},{"key":"ref_41","doi-asserted-by":"crossref","unstructured":"Oe, N., Takeda, H., Eso, Y., Takai, A., and Marusawa, H. (2022). Clinical and molecular basis of hepatocellular carcinoma after hepatitis C virus eradication. Pathogens, 11.","DOI":"10.3390\/pathogens11040430"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1089\/jir.1997.17.355","article-title":"Interferon-beta induces S phase accumulation selectively in human transformed cells","volume":"17","author":"Qin","year":"1997","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1006\/mthe.2001.0464","article-title":"Human and mouse IFN-\u03b2 gene therapy exhibits different anti-tumor mechanisms in mouse models","volume":"4","author":"Qin","year":"2001","journal-title":"Mol. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1089\/10799900260442511","article-title":"Direct evidence that IFN-beta functions as a tumor-suppressor protein","volume":"22","author":"Kaynor","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1089\/107999002760274881","article-title":"Cytotoxicity of combinations of IFN-beta and chemotherapeutic drugs","volume":"22","author":"Brickelmaier","year":"2002","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"14411","DOI":"10.1073\/pnas.95.24.14411","article-title":"Interferon-beta gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice","volume":"95","author":"Qin","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_47","unstructured":"Hoffmann-La Roche, Inc. (2022, May 12). Package Insert: ROFERON\u00ae\u2014A (Interferon alfa-2a, Recombinant), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2006\/103145s5060LBL.pdf."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1634\/theoncologist.2012-0368","article-title":"Pegylated interferon for the adjuvant treatment of melanoma: FDA approved, but what is its role?","volume":"17","author":"Sondak","year":"2012","journal-title":"Oncologist"},{"key":"ref_49","unstructured":"MERCK & Co., Inc. (2022, May 12). Package Insert: SYLATRONTM (Peginterferon alfa-2b), Available online: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/103949Orig1s5310lbl.pdf."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.bbmt.2018.12.078","article-title":"A Phase I\/II clinical trial of type 1 interferon for reduction of relapse after HCT in high risk AML","volume":"25","author":"Magenau","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.ajps.2015.08.011","article-title":"PEGylation in anti-cancer therapy: An overview","volume":"11","author":"Mishra","year":"2016","journal-title":"Asian J. Pharm. Sci."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1038\/leu.2016.121","article-title":"Safety and efficacy of the combination of pegylated interferon-\u03b12b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients","volume":"30","author":"Stentoft","year":"2016","journal-title":"Leukemia"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"769628","DOI":"10.3389\/fonc.2021.769628","article-title":"Recent progress in interferon therapy for myeloid malignancies","volume":"11","author":"Healy","year":"2021","journal-title":"Front. Oncol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e15563","DOI":"10.1097\/MD.0000000000015563","article-title":"Maintenance interferon therapy in chronic hepatitis C patients who failed initial antiviral therapy: A meta-analysis","volume":"98","author":"Hung","year":"2019","journal-title":"Medicine"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"675","DOI":"10.2217\/fon-2019-0845","article-title":"Direct-acting antivirals and interferon-based therapy on hepatocellular carcinoma risk in chronic hepatitis-C patients","volume":"16","author":"Ma","year":"2020","journal-title":"Future Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1182\/blood-2015-04-637280","article-title":"Ropeginterferon alfa-2b, a novel IFN\u03b1-2b, induces high response rates with low toxicity in patients with polycythemia vera","volume":"126","author":"Gisslinger","year":"2015","journal-title":"Blood"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1038\/s41408-018-0133-0","article-title":"Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo","volume":"8","author":"Verger","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_58","first-page":"967","article-title":"Standard and pegylated interferon therapy of HDV infection: A systematic review and meta- analysis","volume":"17","author":"Alavian","year":"2012","journal-title":"J. Res. Med. Sci."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13099-021-00421-9","article-title":"Potential capacity of interferon-\u03b1 to eliminate covalently closed circular DNA (cccDNA) in hepatocytes infected with hepatitis B virus","volume":"13","author":"Wang","year":"2021","journal-title":"Gut Pathog."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.jhep.2016.08.022","article-title":"Reduction of covalently closed circular DNA with long-term nucleos(t)ide analogue treatment in chronic hepatitis B","volume":"66","author":"Lai","year":"2017","journal-title":"J. Hepatol."},{"key":"ref_61","first-page":"2093847","article-title":"Add-on pegylated interferon alpha-2a therapy in chronic hepatitis B Japanese patients treated with entecavir","volume":"2017","author":"Tamai","year":"2017","journal-title":"Hepat. Res. Treat."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1016\/j.jfma.2013.05.011","article-title":"Successful treatment of chronic hepatitis B and D with pegylated-interferon plus entecavir","volume":"114","author":"Chen","year":"2015","journal-title":"J. Formos. Med. Assoc."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1111\/jvh.12418","article-title":"Pegylated interferon alfa for chronic hepatitis B: Systematic review and meta-analysis","volume":"23","author":"Kim","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1007\/s10620-018-5251-9","article-title":"Hepatitis B surface antigen loss with tenofovir disoproxil fumarate plus peginterferon alfa-2a: Week 120 analysis","volume":"63","author":"Ahn","year":"2018","journal-title":"Dig. Dis. Sci."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1093\/infdis\/jix024","article-title":"Pegylated interferon alfa-2b add-on treatment in hepatitis B virus envelope antigen-positive chronic hepatitis B patients treated with nucleos(t)ide analogue: A randomized, controlled trial (PEGON)","volume":"215","author":"Chi","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1097\/CM9.0000000000000857","article-title":"Entecavir add-on Peg-interferon therapy plays a positive role in reversing hepatic fibrosis in treatment-na\u00efve chronic hepatitis B patients: A prospective and randomized controlled trial","volume":"133","author":"Yang","year":"2020","journal-title":"Chin. Med. J."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/jvh.13236","article-title":"Peg-interferon and nucleos(t)ide analogue combination at inception of antiviral therapy improves both anti-HBV efficacy and long-term survival among HBV DNA-positive hepatocellular carcinoma patients after hepatectomy\/ablation","volume":"27","author":"Qi","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_68","unstructured":"WHO (2022, May 12). Hepatitis D Fact Sheets (Updated July 2021). Available online: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/hepatitis-d."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.coph.2021.03.008","article-title":"Current status of hepatitis delta","volume":"58","author":"Papatheodoridi","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1136\/gutjnl-2020-323888","article-title":"Hepatitis D virus in 2021: Virology, immunology and new treatment approaches for a difficult-to-treat disease","volume":"70","author":"Urban","year":"2021","journal-title":"Gut"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1016\/j.jhep.2021.01.014","article-title":"The changing context of hepatitis D","volume":"74","author":"Rizzetto","year":"2021","journal-title":"J. Hepatol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.jhep.2020.02.030","article-title":"Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies","volume":"73","author":"Alfaiate","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Sagnelli, C., Sagnelli, E., Russo, A., Pisaturo, M., Occhiello, L., and Coppola, N. (2021). HBV\/HDV co-Infection: Epidemiological and clinical changes, recent knowledge and future challenges. Life, 11.","DOI":"10.3390\/life11020169"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1056\/NEJMoa0912696","article-title":"Peginterferon plus adefovir versus either drug alone for hepatitis delta","volume":"364","author":"Wedemeyer","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1053\/j.gastro.2004.03.017","article-title":"Long-term benefit of interferon alpha therapy of chronic hepatitis D: Regression of advanced hepatic fibrosis","volume":"126","author":"Farci","year":"2004","journal-title":"Gastroenterology"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hep4.1633","article-title":"Persistent control of hepatitis B virus and hepatitis delta virus infection following REP 2139-Ca and pegylated interferon therapy in chronic hepatitis B virus\/hepatitis delta virus coinfection","volume":"5","author":"Bazinet","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1111\/jvh.13366","article-title":"Ten-year follow-up of a randomized controlled clinical trial in chronic hepatitis delta","volume":"27","author":"Wranke","year":"2020","journal-title":"J. Viral Hepat."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1002\/hep.27102","article-title":"Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta","volume":"60","author":"Heidrich","year":"2014","journal-title":"Hepatology"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s40265-020-01400-1","article-title":"Bulevirtide: First approval","volume":"80","author":"Kang","year":"2020","journal-title":"Drugs"},{"key":"ref_81","unstructured":"European Medicines Agency (2022, May 12). Hepcludex-EPAR-Assessment-Report_en. Available online: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/hepcludex."},{"key":"ref_82","unstructured":"Hepatera Ltd. (2022, May 12). Study Results of ClinicalTrials.gov No. NCT03546621, Last Updated 10 May 2021, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT03546621."},{"key":"ref_83","unstructured":"Hepatera Ltd. (2022, May 12). Study Results of ClinicalTrials.gov No. NCT02888106, Last Updated 30 April 2021, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/results\/NCT02888106."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Yurdaydin, C., Keskin, O., Yurdcu, E., \u00c7ali\u015fkan, A., \u00d6nem, S., Karakaya, F., Kalkan, \u00c7., Karatayli, E., Karatayli, S., and Choong, I. (2021). A phase 2 dose-finding study of lonafarnib and ritonavir with or without interferon alpha for chronic delta hepatitis. Hepatology, Online ahead of print.","DOI":"10.1002\/hep.32259"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1053\/j.gastro.2009.04.048","article-title":"Amphipathic DNA polymers inhibit hepatitis C virus infection by blocking viral entry","volume":"137","author":"Matsumura","year":"2009","journal-title":"Gastroenterology"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1128\/AAC.50.4.1393-1401.2006","article-title":"Phosphorothioate oligonucleotides inhibit human immunodeficiency virus type 1 fusion by blocking gp41 core formation","volume":"50","author":"Vaillant","year":"2006","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1743-422X-6-214","article-title":"Amphipathic DNA polymers exhibit antiviral activity against systemic murine cytomegalovirus infection","volume":"6","author":"Cardin","year":"2009","journal-title":"Virol. J."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1177\/135965350701200810","article-title":"Amphipathic DNA polymers are candidate vaginal microbicides and block herpes simplex virus binding, entry and viral gene expression","volume":"12","author":"Guzman","year":"2007","journal-title":"Antivir. Ther."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e01416","DOI":"10.1128\/JVI.01416-17","article-title":"Nucleic acid polymers are active against hepatitis delta virus infection in vitro","volume":"92","author":"Beilstein","year":"2018","journal-title":"J. Virol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"5299","DOI":"10.1128\/AAC.01005-13","article-title":"Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo","volume":"57","author":"Noordeen","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Al-Mahtab, M., Bazinet, M., and Vaillant, A. (2016). Safety and efficacy of nucleic acid polymers in monotherapy and combined with immunotherapy in treatment-naive bangladeshi patients with HBeAg+ chronic hepatitis B infection. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0156667"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/S2468-1253(17)30288-1","article-title":"Safety and efficacy of REP 2139 and pegylated interferon alfa-2a for treatment-naive patients with chronic hepatitis B virus and hepatitis D virus co-infection (REP 301 and REP 301-LTF): A non-randomised, open-label, phase 2 trial","volume":"2","author":"Bazinet","year":"2017","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"4215","DOI":"10.1128\/JVI.02844-06","article-title":"Characterization of hepatitis B virus (HBV)-specific T-cell dysfunction in chronic HBV infection","volume":"81","author":"Carolina","year":"2007","journal-title":"J. Virol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1089\/vim.2015.0062","article-title":"Expression of PD-L1 on CD4+CD25+Foxp3+ regulatory T Cells of patients with chronic HBV infection and its correlation with clinical parameters","volume":"28","author":"Feng","year":"2015","journal-title":"Viral Immunol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Tzeng, H.-T., Tsai, H.-F., Liao, H.-J., Lin, Y.-J., Chen, L., Chen, P.-J., and Hsu, P.-N. (2012). PD-1 blockage reverses immune dysfunction and hepatitis B viral persistence in a mouse animal model. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0039179"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Liu, J., Zhang, E., Ma, Z., Wu, W., Kosinska, A., Zhang, X., M\u00f6ller, I., Seiz, P., Glebe, D., and Wang, B. (2014). Enhancing virus-specific immunity in vivo by combining therapeutic vaccination and PD-L1 blockade in chronic hepadnaviral infection. PLoS Pathog., 10.","DOI":"10.1371\/journal.ppat.1003856"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1016\/S0140-6736(17)31046-2","article-title":"Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1\/2 dose escalation and expansion trial","volume":"389","author":"Sangro","year":"2017","journal-title":"Lancet"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"e19013","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: A systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/CJI.0000000000000358","article-title":"Hepatitis B virus reactivation in cancer patients treated with immune checkpoint inhibitors","volume":"44","author":"Burns","year":"2021","journal-title":"J. Immunother."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.jhepr.2019.07.007","article-title":"Is PD-1 blockade a potential therapy for HBV?","volume":"1","year":"2019","journal-title":"JHEP Rep."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1089\/10799900260100222","article-title":"CD4+ T helper cell-independent antitumor response mediated by murine IFN-beta gene delivery in immunocompetent mice","volume":"22","author":"Brown","year":"2002","journal-title":"J. Interferon Cytokine Res."}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/6\/1128\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:18:02Z","timestamp":1760138282000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/6\/1128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5,25]]},"references-count":102,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["v14061128"],"URL":"https:\/\/doi.org\/10.3390\/v14061128","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5,25]]}}}